News Release

Printer Friendly Version View printer-friendly version << Back
November 9, 2000 at 12:00 AM EST

Quidel Introduces New and Improved Test for Peptic Ulcers

SAN DIEGO, Nov. 9 /PRNewswire/ -- Quidel Corporation (Nasdaq: QDEL) announced today the market introduction of its new and improved QuickVue(R) H. pylori gII(TM) test for the diagnosis of peptic ulcer disease. This much-anticipated point-of-care diagnostic product will improve testing for H. pylori by speeding results and reducing sample volume requirements, allowing health care providers to deliver better patient care.

"Over twenty-five million Americans are expected to suffer from peptic ulcers during their lifetime and the Centers for Disease Control and Prevention estimates that $6 billion is spent annually on treatment for this disease," said Andre de Bruin, Vice Chairman, President and Chief Executive Officer of Quidel Corporation. "Many people are unaware that H. pylori bacteria causes an estimated 90% of duodenal ulcers and more than 80% of all gastric ulcers. Testing for H. pylori and treating this infection with antibiotic therapy is currently the lowest cost and most effective option for ulcer disease management. We are delighted to be launching this important diagnostic test following National Ulcer Awareness Week."

Quidel Corporation discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women's health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis. Quidel's products are sold to healthcare professionals for use in physicians' offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information to enable rapid treatment and improve health outcomes, lower costs, and increase patient satisfaction.

This press release contains forward-looking statements regarding Quidel's future activities within the meaning of the federal securities laws. These forward-looking statements involve material risks and uncertainties. Many possible factors could affect the future results and performance of Quidel's products, such that actual results and performance may differ materially. If Quidel's products fail to perform as expected, or if there is lower consumer demand for these products than expected, Quidel's financial condition and operating results may be materially and adversely affected. Quidel's financial condition and operating results may also be materially and adversely affected by a number of other factors, including, without limitation, seasonality, adverse changes in competitive and economic conditions, actions by the Company's distributors, manufacturing and production delays or difficulties and adverse actions or delays in product reviews by the FDA. Please see the discussion of these and other factors in Quidel's annual reports on Form 10-K and subsequent quarterly reports on Form 10-Q. For more information, please visit Quidel's web site at http://www.quidel.com.

Charles J. Cashion, Chief Financial Officer of Quidel Corporation, 858-552-7962,
or Miriam Weber Vice President Noonan/Russo Communications, 212-696-4455, ext. 352 for Quidel Corporation.